Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.

Cold Spring Harbor perspectives in medicine - 1 Aug 2018

Aguirre Andrew J, Hahn William C

Abstract excerpt

KRAS is the most commonly mutated oncogene in human cancer. Most KRAS-mutant cancers depend on sustained expression and signaling of KRAS, thus making it a high-priority therapeutic target. Unfortunately, development of direct small molecule inhibitors of KRAS function has been challenging. An alternative therapeutic strategy for KRAS-mutant malignancies involves targeting codependent vulnerabilities or synthetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor
Share to KRAS gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 29101114
DOI: 10.1101/cshperspect.a031518
PMCID: PMC5990478

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.PMID 29101114Read ↗

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.Semantic proximity Read ↗

KRAS Alleles: The Devil Is in the Detail.Semantic proximity Read ↗

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.Semantic proximity Read ↗

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.Semantic proximity Read ↗

Targeting KRAS mutant cancers: from druggable therapy to drug resistance.Semantic proximity Read ↗

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors.Semantic proximity Read ↗

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Semantic proximity Read ↗

Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers.Semantic proximity Read ↗

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancerSemantic proximity Read ↗

KRAS Pathways: A Potential Gateway for Cancer Therapeutics and Diagnostics.Semantic proximity Read ↗

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.Semantic proximity Read ↗

Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.